QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY

被引：0

作者：

Augustin, Matthias ^{[1
]}

Sommer, Raquel ^{[1
]}

Reguiai, Ziad ^{[2
]}

Gerdes, Sascha ^{[3
]}

Dauden, Esteban ^{[4
]}

Weger, Wolfgang ^{[5
]}

Maul, Julia-Tatjana ^{[6
,7
]}

Laws, Philip ^{[8
]}

Naldi, Luigi ^{[9
]}

Ghislain, Pierre-Dominique ^{[10
]}

de Jong, Elke ^{[11
]}

Mburu, Sicily ^{[12
]}

Koscielny, Volker ^{[13
]}

Massana, Eric ^{[13
]}

Kasujee, Ismail ^{[13
]}

Mrowietz, Ulrich ^{[14
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany

[2] Polyclin Courlancy Bezannes, Dermatol Dept, Reims, France

[3] Univ Med Ctr Schleswig Holstein, Ctr Inflammatory Skin Dis, Dept Dermatol Venereol & Allergol, Campus Kiel, Kiel, Germany

[4] La Princesa Univ Hosp, Inst Invest Sanitaria La Princesa IIS IP, Madrid, Spain

[5] Med Univ Graz, Dept Dermatol & Venereol, Graz, Austria

[6] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland

[7] Univ Zurich, Fac Med, Zurich, Switzerland

[8] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England

[9] San Bortolo Hosp, Div Dermatol, Vicenza, Italy

[10] Catholic Univ Louvain, Clin Univ St Luc, Dept Dermatol, Brussels, Belgium

[11] Radboud Univ Nijmegen, Med Ctr, Radboudumc, Dept Dermatol, Nijmegen, Netherlands

[12] Int Federat Psoriasis Assoc, Stockholm, Sweden

[13] Almirall GMA, Barcelona, Spain

[14] Univ Med Ctr Schleswig Holstein, Psoriasis Ctr, Dept Dermatol, Campus Kiel, Kiel, Germany

来源：

ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P-057

引用

页数：102

共 50 条

[1] Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
Torres, Tiago
Varela, Paulo
Bastos, Pedro Mendes
Magina, Sofia
Henrique, Martinha
Ferreira, Paulo
[J]. DRUGS IN CONTEXT, 2024, 13
[2] Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
Bhatia, Neal
Vasquez, J. Gabriel
Schenkel, Brad
Rozzo, Stephen J.
Heim, Jayme
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB72 - AB72
[3] Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
Gnesotto, Laura
Mioso, Guido
Bardazzi, Federico
Filippi, Federica
Di Lernia, Vito
Motolese, Alberto
Di Nuzzo, Sergio
Conti, Andrea
Arginelli, Federica
Corazza, Monica
Odorici, Giulia
Borghi, Alessandro
Gisondi, Paolo
Naldi, Luigi
Dapavo, Paolo
Parodi, Aurora
Burlando, Martina
Piaserico, Stefano
[J]. ACTA DERMATO-VENEREOLOGICA, 2023, 103
[4] Patients' quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
Heim, Jayme
Vasquez, J. Gabriel
Rozzo, Stephen J.
Schenkel, Brad
Bhatia, Neal
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB204 - AB204
[5] Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
Bhatia, Neal
Heim, Jayme
Schenkel, Brad
Vasquez, J. Gabriel
[J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
[6] 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience
Ramos, F. J. Melgosa
Puchades, A. Mateu
Mataix-Diaz, J.
Schneller-Pavelescu, L.
Belinchon-Romero, I.
Alarcon, S. Santos
[J]. ACTAS DERMO-SIFILIOGRAFICAS, 2024, 115 (07): : T722 - T726
[7] EFFECTIVENESS AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS LOCATED IN SPECIAL AREAS: 52-WEEK RESULTS FROM THE POSITIVE STUDY
Sommer, Rachel
Augustin, Matthias
Reguiai, Ziad
Gerdes, Sascha
Dauden, Esteban
Weger, Wolfgang
Maul, Julia-Tatjana
Laws, Philip
Naldi, Luigi
Ghislain, Pierre -Dominique
de Jong, Elke
Mburu, Sicily
Koscielny, Volker
Massana, Eric
Kasujee, Ismail
Mrowietz, Ulrich
[J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
[8] A Phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
Heim, Jayme
Vasquez, J. Gabriel
Beute, Paulita
Torres, Monique
Rozzo, Stephen J.
Bhatia, Neal
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 6
[9] A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
Heim, Jayme
Vasquez, J. Gabriel
Beute, Paulita
Torres, Monique
Rozzo, Stephen J.
Bhatia, Neal
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB132 - AB132
[10] EFFECTIVENESS OF TILDRAKIZUMAB FOR ITCH, PAIN, AND FATIGUE IN PATIENTS WITH MODERATETO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM THE REAL-WORLD POSITIVE STUDY
Mrowietz, Ulrich
Augustin, Matthias
Reguiai, Ziad
Des, Sascha Ger-
Dauden, Esteban
Weger, Wolfgang
Maul, Julia-Tatjana
Laws, Philip
Naldi, Luigi
Ghislain, Pierre -Dominique
de Jong, Elke
Mburu, Sicily
Koscielny, Volker
Massana, Eric
Kasujee, Ismail
Sommer, Raquel
[J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104

← 1 2 3 4 5 →